|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
THIAZIDE DIURETICS CONCOMITANT USE MAY LEAD TO TOXIC BLOOD LEVELS OF THE DRUG
|
ANTAGONISE URICOSURIC EFFECT & SALICYLATES ALSO ENHANCE URINARY EXCRETION OF ALLOPURINAL
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THIAZIDE DIURETICS CONCOMITANT USE MAY LEAD TO TOXIC BLOOD LEVELS OF THE DRUG
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ALLOPURINOL REDUCES RENAL CLEARANCE OF THE DRUG SO THE DRUG DOSE SHOULD BE REDUCED TO 1/3 OR 1/4
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
ALLOPURINOL REDUCES RENAL CLEARANCE OF THE DRUG SO THE DRUG DOSE SHOULD BE REDUCED TO 1/3 OR 1/4
|
ADDITIVE MYELOSUPPRESSION WHEN USED WITH OTHER MYELOSUPPRESSIVE DRUGS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTAGONISE URICOSURIC EFFECT & SALICYLATES ALSO ENHANCE URINARY EXCRETION OF ALLOPURINAL
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
ANTAGONISE URICOSURIC EFFECT & SALICYLATES ALSO ENHANCE URINARY EXCRETION OF ALLOPURINAL
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
THIAZIDE DIURETICS CONCOMITANT USE MAY LEAD TO TOXIC BLOOD LEVELS OF THE DRUG
|
THIAZIDE DIURETICS CONCOMITANT USE MAY LEAD TO TOXIC BLOOD LEVELS OF THE DRUG
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
THIAZIDE DIURETICS CONCOMITANT USE MAY LEAD TO TOXIC BLOOD LEVELS OF THE DRUG
|
ANTAGONISE URICOSURIC EFFECT & SALICYLATES ALSO ENHANCE URINARY EXCRETION OF ALLOPURINAL
|
ANTAGONISE URICOSURIC EFFECT & SALICYLATES ALSO ENHANCE URINARY EXCRETION OF ALLOPURINAL
|
ANTAGONISE URICOSURIC EFFECT & SALICYLATES ALSO ENHANCE URINARY EXCRETION OF ALLOPURINAL
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
ALLUPURINOL & AMPICILLIN CONCURRENT ADMINISTRATION SUBSTANTIALLY INCREASE THE INCIDENCE OF RASHES IN PATIENTS RECIEVING BOTH DRUGS AS COMPARED TO PATIENTS RECIEVING AMPICILLIN ALONE
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
THIAZIDE DIURETICS CONCOMITANT USE MAY LEAD TO TOXIC BLOOD LEVELS OF THE DRUG
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
ALLOPURINOL REDUCES RENAL CLEARANCE OF THE DRUG SO THE DRUG DOSE SHOULD BE REDUCED TO 1/3 OR 1/4
|
ANTAGONISE URICOSURIC EFFECT & SALICYLATES ALSO ENHANCE URINARY EXCRETION OF ALLOPURINAL
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ALLUPURINOL INCREASES BOTH PLASMA LEVELS AND HALF LIFE OF THE DRUG LEADING TO INCREASED CHANCES OF TOXICITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
ALLOPURINOL REDUCES RENAL CLEARANCE OF THE DRUG SO THE DRUG DOSE SHOULD BE REDUCED TO 1/3 OR 1/4
|
ANTAGONISE URICOSURIC EFFECT & SALICYLATES ALSO ENHANCE URINARY EXCRETION OF ALLOPURINAL
|
ALLOPURINOL REDUCES RENAL CLEARANCE OF THE DRUG SO THE DRUG DOSE SHOULD BE REDUCED TO 1/3 OR 1/4
|
CO-ADMINISTRATION OF ALLOPURINOL AND AMPICILLIN INCREASES SUBSTANTIALLY THE INCIDENCE OF RASHES
|
ALLUPURINOL & BACAMPICILLIN CONCURRENT ADMINISTRATION SUBSTANTIALLY INCREASE THE INCIDENCE OF RASHES IN PATIENTS RECIEVING BOTH DRUGS AS COMPARED TO PATIENTS RECIEVING AMPICILLIN ALONE
|
ANTAGONISE URICOSURIC EFFECT & SALICYLATES ALSO ENHANCE URINARY EXCRETION OF ALLOPURINAL
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
ALLOPURINOL REDUCES RENAL CLEARANCE OF THE DRUG SO THE DRUG DOSE SHOULD BE REDUCED TO 1/3 OR 1/4
|
ALLUPURINOL & AMPICILLIN CONCURRENT ADMINISTRATION SUBSTANTIALLY INCREASE THE INCIDENCE OF RASHES IN PATIENTS RECIEVING BOTH DRUGS AS COMPARED TO PATIENTS RECIEVING AMPICILLIN ALONE
|
THIAZIDE DIURETICS CONCOMITANT USE MAY LEAD TO TOXIC BLOOD LEVELS OF THE DRUG
|
ANTAGONISE URICOSURIC EFFECT & SALICYLATES ALSO ENHANCE URINARY EXCRETION OF ALLOPURINAL
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
ALLOPURINOL REDUCES RENAL CLEARANCE OF THE DRUG SO THE DRUG DOSE SHOULD BE REDUCED TO 1/3 OR 1/4
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
ANTAGONISE URICOSURIC EFFECT & SALICYLATES ALSO ENHANCE URINARY EXCRETION OF ALLOPURINAL
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
THIAZIDE DIURETICS CONCOMITANT USE MAY LEAD TO TOXIC BLOOD LEVELS OF THE DRUG
|
THIAZIDE DIURETICS CONCOMITANT USE MAY LEAD TO TOXIC BLOOD LEVELS OF THE DRUG
|
THIAZIDE DIURETICS CONCOMITANT USE MAY LEAD TO TOXIC BLOOD LEVELS OF THE DRUG
|
THIAZIDE DIURETICS CONCOMITANT USE MAY LEAD TO TOXIC BLOOD LEVELS OF THE DRUG
|
THIAZIDE DIURETICS CONCOMITANT USE MAY LEAD TO TOXIC BLOOD LEVELS OF THE DRUG
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ADDITIVE MYELOSUPPRESSION WHEN USED WITH OTHER MYELOSUPPRESSIVE DRUGS
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|